Abstract
Human respiratory syncytial virus (hRSV) is one of the most common causes of respiratory infection in infants and the elderly. Previous attempts to vaccinate children against RSV failed and the induction of an aberrant Th2-type immune response was shown to induce severe to fatal pulmonary disease characterised in part by eosinophilia. BBG2Na is a promising human RSV subunit vaccine candidate which successfully passed phase II clinical trials in adults in association with Adju-Phos((R)). However, this formulation is not the most suitable for use in children since aluminium salts are known to induce a Th2-based immune response. In this study, we describe a potent and safe adjuvant formulation for BBG2Na in dimethyldioctadecylammonium bromide (DDA) that induces a mixed Th1/Th2 immune response in BALB/c mice. Furthermore, BBG2Na showed the same protective efficacy against RSV challenge when formulated either in DDA or in alum in mice and cotton rats.
MeSH terms
-
Adjuvants, Immunologic*
-
Animals
-
Female
-
Interferon-gamma / metabolism
-
Interleukin-4 / metabolism
-
Interleukin-5 / metabolism
-
Mice
-
Mice, Inbred BALB C
-
Quaternary Ammonium Compounds / pharmacology
-
Rats
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Infections / virology
-
Respiratory Syncytial Virus Vaccines / administration & dosage*
-
Respiratory Syncytial Virus Vaccines / adverse effects
-
Respiratory Syncytial Virus Vaccines / immunology*
-
Sigmodontinae
-
Th1 Cells / immunology*
-
Th2 Cells / immunology*
-
Vaccines, DNA / administration & dosage*
-
Vaccines, DNA / adverse effects
-
Vaccines, DNA / immunology
-
Viral Proteins / genetics
-
Viral Proteins / immunology*
Substances
-
Adjuvants, Immunologic
-
BBG2Na vaccine
-
Interleukin-5
-
Quaternary Ammonium Compounds
-
Respiratory Syncytial Virus Vaccines
-
Vaccines, DNA
-
Viral Proteins
-
Interleukin-4
-
dimethyldioctadecylammonium
-
Interferon-gamma